AIM ImmunoTech Inc - Company Profile
Powered by 
All the sales intelligence you need on AIM ImmunoTech Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AIM ImmunoTech Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AIM ImmunoTech Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
AIM ImmunoTech Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing therapies for viral and immune-related diseases. The company’s core approach leverages nucleic-acid–based immunomodulators and natural interferon to stimulate the body’s innate antiviral defenses and enhance immune responses.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D activities focus on expanding the market potential of Ampligen through investigating its efficacy in various immune-based disorders, including cancer, chronic fatigue syndrome (CFS), and COVID-19. The company has been involved in multiple clinical trials to explore Ampligen's potential as an immuno-oncology therapeutic, particularly in combination with checkpoint inhibitors. Additionally, AIM ImmunoTech has been researching Ampligen's potential prophylactic and therapeutic applications for COVID-19 and its long-term effects. The company has also explored Ampligen's antiviral properties and its potential use in treating other diseases such as Ebola and Alzheimer's disease. In FY2025, the company spent US$3.5 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer